Reading OGN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OGN free→Reading OGN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OGN free→QuarterlyIQ Insights · OGN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The stockholders of Organon & Co. (the “ Company ”) approved an amendment and restatement of the Organon & Co. 2021 Incentive Stock Plan (the “ Amended and Restated 2021 ISP ”) at the Company’s 2026 Annual Meeting held on June 9, 2026 (the “ Annual Meeting ”). The Company’s Board of Directors (the “ Board ”), upon the…
Results of Operations and Financial Condition. On April 30, 2026, Organon & Co. (the “ Company ”) issued a press release (the “ Earnings Release ”) regarding its results for the quarter ended March 31, 2026. A copy of the Earnings Release is included as Exhibit 99.1 to this report. The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is considered to be “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934…
Entry into a Material Definitive Agreement. On April 26, 2026, Organon & Co. (the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Sun Pharmaceutical Holdings USA, Inc., a Delaware corporation (“ Parent ”), Sun Pharma America, Inc., a Delaware corporation and wholly owned subsidiary of Parent and/or its affiliates (“ Merger Sub ”) and, solely for the purposes of certain covered provisions of the Merger Agreement, Sun Pharmaceutical Industries Limited,…
from, the Company’s definitive proxy statement for its 2026 Annual Meeting of Stockholders, filed with the U.S. Securities and Exchange Commission (the “ SEC ”) on April 24, 2026 (the “ 2026 Annual Meeting Proxy Statement ”). No changes were made to Mr. Morrissey’s compensation or benefits in connection with the appointment to Chief Executive Officer of the Company on a permanent basis. Appointment of Executive Chair As previously disclosed in a Current Report on Form 8-K filed by the Company…
Regulation FD Disclosure. On April 26, 2026, the Company and Parent issued a joint press release announcing the entry into the Merger Agreement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is considered to be “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liab…
Other Events. As previously disclosed on February 12, 2026, the Audit Committee of the Board of Directors of Organon & Co. (the “ Company ”) conducted an independent review of the information brought to the Audit Committee’s attention on February 11, 2026 relating to the timing of the Company’s purchases of biosimilars from a supplier in prior years. The Audit Committee has completed its independent review with the assistance of outside counsel. The review determined that no action is require…
Results of Operations and Financial Condition. On February 12, 2026, Organon & Co. (the “ Company ”) issued a press release (the “ Earnings Release ”) regarding its results for the quarter and full year ended December 31, 2025. A copy of the Earnings Release is included as Exhibit 99.1 to this report. The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is considered to be “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.